Comment on the JAVELIN study: RCC immunotherapy

Bookmark and Share
Published: 21 Oct 2018
Views: 1527
Prof John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Prof Jon Haanan comments at ESMO 2018 on the JAVELIN Renal 101 study for the use of avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma.

For more on these findings, watch Dr Motzer present the trial findings at the conference.